Omega licenses OTC skin lesion treatment

5 January 2015 - Deborah Wilkes

Archived

Omega Pharma is in-licensing the OTC rights to BioLineRx's skin lesion treatment, BL-5010, in Europe, Australia and a number of additional countries. Rights in the US and the rest of the world will be retained by the Israeli product development company.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: